Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
PD-L1
T-cell inflammation
immunotherapy
pancreatic cancer
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
01
2022
accepted:
23
03
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
The immune contexture of pancreatic ductal adenocarcinoma (PDAC) is generally immunosuppressive. A role for immune checkpoint inhibitors (ICIs) in PDAC has only been demonstrated for the rare and hypermutated mismatch repair (MMR) deficient (MMR-d) subtype. Homologous recombination repair (HR) deficient (HR-d) PDAC is more prevalent and may encompass up to 20% of PDAC. Its genomic instability may promote a T-cell mediated anti-tumor response with therapeutic sensitivity to ICIs. To investigate the immunogenicity of HR-d PDAC, we used multiplex immunohistochemistry (IHC) to compare the density and spatial distribution of CD8+ cytotoxic T-cells, FOXP3+ regulatory T-cells (Tregs), and CD68+ tumor-associated macrophages (TAMs) in HR-d
Identifiants
pubmed: 35547873
doi: 10.3389/fonc.2022.860767
pmc: PMC9082359
doi:
Types de publication
Journal Article
Langues
eng
Pagination
860767Informations de copyright
Copyright © 2022 Golesworthy, Wang, Tanti, Pacis, Romero, Cuggia, Domecq, Bourdel, Denroche, Jang, Grant, Borgida, Grünwald, Dodd, Wilson, Bourque, O’Kane, Fischer, Kron, Fiset, Omeroglu, Foulkes, Gallinger, Guiot, Gao and Zogopoulos.
Déclaration de conflit d'intérêts
P-OF has received honoraria from EMD Serono and consultation fees from Amgen, Bristol Myers Squibb, AstraZeneca Canada, Hoffmann La Roche, Merck Canada, Pfizer Canada and Roche Canada. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gastroenterology. 2021 May;160(6):2119-2132.e9
pubmed: 33524400
Semin Oncol. 2021 Feb;48(1):19-33
pubmed: 33637355
Cancer Lett. 2020 Oct 10;490:174-185
pubmed: 32721551
Gut. 2021 Jan;70(1):148-156
pubmed: 32350089
JAMA Oncol. 2017 Jun 01;3(6):774-783
pubmed: 27768182
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
Mod Pathol. 2019 Mar;32(3):367-375
pubmed: 30297881
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Gut. 2021 Oct;70(10):1894-1903
pubmed: 32933947
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Gut. 2017 Sep;66(9):1665-1676
pubmed: 27325420
JCO Precis Oncol. 2018 Nov;2:1-16
pubmed: 35135108
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Eur J Cancer. 2020 Jun;132:71-84
pubmed: 32334338
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697
pubmed: 30635425
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Genes (Basel). 2020 Sep 21;11(9):
pubmed: 32967105
Curr Oncol. 2015 Apr;22(2):113-21
pubmed: 25908910
Ann Surg Oncol. 2020 Oct;27(10):3997-4006
pubmed: 32108923
Ann Oncol. 2017 Dec 1;28(12):2950-2961
pubmed: 28945842
Gastroenterology. 2018 Dec;155(6):1999-2013.e3
pubmed: 30165049
Clin Cancer Res. 2020 Sep 15;26(18):4901-4910
pubmed: 32156747
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Clin Cancer Res. 2020 Apr 15;26(8):1997-2010
pubmed: 31964786
Eur J Immunol. 2021 Apr;51(4):956-964
pubmed: 33506525
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
J Natl Cancer Inst. 2021 Feb 1;113(2):182-191
pubmed: 32497200
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Nat Cancer. 2021 Dec;1(12):1188-1203
pubmed: 33834176
Clin Cancer Res. 2018 Mar 15;24(6):1344-1354
pubmed: 29288237
AAPS J. 2020 Nov 22;23(1):5
pubmed: 33222057
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
JAMA. 2018 Jun 19;319(23):2401-2409
pubmed: 29922827
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
J Clin Oncol. 2015 Oct 1;33(28):3124-9
pubmed: 25940717
JAMA Oncol. 2015 Apr;1(1):23-32
pubmed: 26182300
Clin Cancer Res. 2020 Oct 15;26(20):5462-5476
pubmed: 32816949
Cancer Discov. 2020 Mar;10(3):422-439
pubmed: 31911451
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
J Clin Oncol. 2020 May 1;38(13):1378-1388
pubmed: 31976786
Gastroenterology. 2015 Mar;148(3):556-64
pubmed: 25479140
PLoS Genet. 2019 Aug 30;15(8):e1008344
pubmed: 31469826
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110